Amgen (AMGN) Goldman Sachs 45th Annual Global Healthcare Conference summary

Strategic vision and growth outlook

• Emphasizing a transformative period with global expansion and a diverse, innovative pipeline across four therapeutic pillars: general medicine, oncology, inflammation, and rare disease.

• Strong confidence in long-term growth through the end of the decade, driven by marketed products and late-stage pipeline assets.

• Recent approvals and positive data for key products, including IMDELLTRA, BLINCYTO, TEZSPIRE, and UPLIZNA, support momentum.

• Rare disease portfolio highlighted as a major growth driver, with multiple Phase III readouts expected this year.

• Continued value creation for patients, staff, and shareholders through innovation and biosimilars.

Pipeline and clinical development highlights

• MariTide Phase II study completed; broad Phase III program in planning, with manufacturing expansion underway.

• MariTide positioned as a differentiated obesity therapy, with monthly or less frequent single injection administration.

• Platform approach to obesity includes both injectable and oral programs targeting incretin and non-incretin pathways.

• Olpasiran OCEAN(a) Phase III study nearing completion, targeting Lp(a) reduction for cardiovascular risk; quarterly dosing and >95% reduction in Phase II.

• TEZSPIRE advancing to Phase III in COPD, with significant benefit in patients with high eosinophil counts.

• Rocatinlimab Phase III readout in atopic dermatitis expected by year-end, offering an alternative mechanism to existing therapies.

Manufacturing and operational capacity

• New drug substance plant in North Carolina to be operational and licensed in 2026, supporting future growth.

• Highly automated packaging plant in Ohio opened in Q1, enhancing supply chain efficiency.

• Manufacturing network demonstrated resilience during COVID and is calibrated for future large-scale launches.